eligibility_summary
Eligible: Stage I NSCLC, candidate for minimally invasive resection, adequate organ function, ECOG ≤2, contraception if fertile, consent. Exclude: prior systemic therapy/radiation, disorders hindering adherence, anemia, thrombocytopenia, leukopenia/low ANC, low Mg/K/Ca, TSH>13, recent investigational drug, recent major cardiac/CVA/CHF/liver/angina, QT prolongation or class IA/III antiarrhythmics, infusion reactions/hypersensitivity to cetuximab, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial testing cetuximab-IRDye800 for intraoperative near-infrared (NIR) molecular imaging during minimally invasive resection of early-stage NSCLC. Intervention: IV 100 mg cetuximab (chimeric IgG1 anti-EGFR monoclonal antibody) plus 50 mg cetuximab-IRDye800 (antibody–fluorophore conjugate with IRDye800CW, targeted diagnostic imaging agent) given 2–5 days pre-op. Mechanism: cetuximab binds EGFR, blocking ligand-induced signaling and serving as a carrier to deliver an NIR dye that fluoresces to highlight tumors/lymph nodes during VATS/RATS. Cells/pathways targeted: EGFR-overexpressing epithelial tumor cells and metastatic deposits, EGFR/HER family signaling and downstream MAPK/PI3K–AKT pathways. Goal: real-time visualization of non-visible lung nodules and occult nodal metastases to improve localization, staging, margins, and lymphadenectomy.